Compare VTS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | ESPR |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.5M | 731.9M |
| IPO Year | 2022 | 2013 |
| Metric | VTS | ESPR |
|---|---|---|
| Price | $18.19 | $3.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $8.75 |
| AVG Volume (30 Days) | 406.6K | ★ 16.9M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | N/A | ★ N/A |
| Revenue | $273,989,000.00 | ★ $403,135,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.22 | ★ 21.31 |
| 52 Week Low | $17.22 | $0.79 |
| 52 Week High | $27.15 | $4.18 |
| Indicator | VTS | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 70.22 |
| Support Level | $17.42 | $3.11 |
| Resistance Level | $20.13 | $3.18 |
| Average True Range (ATR) | 0.50 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 41.53 | 21.43 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.